Oncology

Pharmaceutical companies and clinical oncology teams are collaborating to harness large sets of patient data, paving the way for more informed and individualized decision-making about treatments.

As oncology spending rises, insurers and manufacturers are looking to specialty pharmacy programs to maximize the effectiveness of cancer therapies.

There are several key factors a specialty pharmacy must consider when deciding whether to participate in a limited distribution network.

New drug approvals include therapies for patients with breast cancer, thyroid cancer, neuroblastoma, and multiple myeloma.

Cost containment of medications for the treatment of cancer is an area of increasing concern for specialty pharmacy stakeholders.

Nivolumab extends life by 3.2 months compared with chemotherapy.

Nivolumab has increased the survival rate in patients with low grade adverse events.

Extracts show strong activity in treatment of cervical cancer cells.

Combination therapy with AKT inhibitors shows promise.

Chemotherapy combination extends progression-free survival over standard chemotherapy.

Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands.

Research seeks to determine how cancer cells avoid chemotherapy.

High level of benefit found in Gazyva compared with bendamustine.

Test projects which agent will work best against particular tumors.

Melanoma incidence increased 250% in children, adolescents and young adults since 1973.

Gene mutations found in some patients provide hope for new and existing treatments.

A pair of large RNA classes associated with a protein that may play a role in cancer progression.

Uncertainty persists in how collagen influences cancer cell behavior.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Treatment advances have caused significant progress in survivorship.

Protein that helps cancer cells avoid death offers promising target.

Smokers face high risk of disease recurrence after completing treatment.

Investigational drug will move to phase 3 studies.

Treatment prior to surgery leads to fewer side effects and better quality of life.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Anti-PDL1 agent with standard chemotherapy combination will now move to multiple phase 3 studies.

Study finds benefits from reduced absenteeism and improved workplace productivity.